<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095381</url>
  </required_header>
  <id_info>
    <org_study_id>BCX1777-T-04-201</org_study_id>
    <nct_id>NCT00095381</nct_id>
    <nct_alias>NCT00086788</nct_alias>
  </id_info>
  <brief_title>Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia</brief_title>
  <official_title>A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their&#xD;
      growth. The Phase II trial is designed to study the effectiveness of BCX-1777 in treating&#xD;
      patients who have recurrent or refractory advanced T-cell leukemia.&#xD;
&#xD;
      Patients will receive an infusion of BCX-1777 on days 1-5. Treatment may be repeated every&#xD;
      week for up to six courses. Patients are not required to be hospitalized for the&#xD;
      administration of BCX-1777. Some patients may continue to receive an infusion of BCX-1777&#xD;
      twice a week for 6 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their&#xD;
      growth. The Phase II trial is designed to study the effectiveness of BCX-1777 in treating&#xD;
      patients who have recurrent or refractory advanced T-cell leukemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the sustained effectiveness of IV forodesine hydrochloride infusions in patients with advanced T-cell leukemia (T-ALL or T-PLL)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) and Pharmacodynamics (PD)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maintenance of response and safety in long-term treatment</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>Leukemia, T-Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>forodesine hydrochloride (BCX-1777)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented T-cell leukemia (precursor T-lymphoblastic leukemia/lymphomia or T-PLL)&#xD;
&#xD;
          -  Failure to have responded to one or more standard regimens for their disease.&#xD;
&#xD;
          -  Performance status of &lt;=2 by Eastern Cooperative Oncology Group (ECOG) criteria&#xD;
&#xD;
          -  All ages are eligible&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Adequate liver function (aspartate transaminase [AST] and/or alanine transaminase&#xD;
             [ALT] not &gt;3 times upper limits or normal [ULN])&#xD;
&#xD;
          -  Adequate kidney function (calculated creatinine clearance &gt;50 mL/min)&#xD;
&#xD;
          -  Negative urine pregnancy test within 2 to 7 days prior to the start of study&#xD;
             treamtment in females of childbearing potential&#xD;
&#xD;
          -  Females of childbearing potential and males must be willing and able to use an&#xD;
             adequate method of contraception to avoid pregnancy for the duration of the study&#xD;
&#xD;
          -  Signed informed consent/assent form (ICF) prior to start of any study specific&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known HIV infection or human T-cell leukemia virus type (HTLV-1)&#xD;
&#xD;
          -  Patients with known Hepatitis B and/or Hepatitis C active infection&#xD;
&#xD;
          -  Patients with active CMV infection&#xD;
&#xD;
          -  Tumor-related central nervous system (CNS) leukemia requiring active treatment&#xD;
&#xD;
          -  Active serious infection not controlled by oral or IV antibiotics&#xD;
&#xD;
          -  Treatment with any investigational anti-leukemic agent or chemotherapy agent within 7&#xD;
             days prior to study entry, unless full recovery from side effects has occurred.&#xD;
&#xD;
          -  Rapidly progressive disease with compromised organ function judged to be&#xD;
             life-threatening by the investigator&#xD;
&#xD;
          -  Concurrent treatment with other anticancer agents (corticosteroid use will not be&#xD;
             excluded, but patient must remain on the stable dose)&#xD;
&#xD;
          -  Cutaneous T-cell lymphoma (CTCL) diagnosis (including Sezary Syndrome)&#xD;
&#xD;
          -  Pregnant and/or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lecanto</city>
        <state>Florida</state>
        <zip>34461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rolla</city>
        <state>Missouri</state>
        <zip>65401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weil Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tbilisi</city>
        <zip>GE-380079</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>November 3, 2004</study_first_submitted>
  <study_first_submitted_qc>November 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2004</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia, Lymphocytic, T-Cell</keyword>
  <keyword>Entry Term Lymphocytic Leukemia, T-Cell</keyword>
  <keyword>T-Cell Leukemia</keyword>
  <keyword>T-Lymphocytic Leukemia</keyword>
  <keyword>Leukemia, Lymphocytic, T Cell</keyword>
  <keyword>T Lymphocytic Leukemia</keyword>
  <keyword>BCX-1777</keyword>
  <keyword>forodesine hydrochloride</keyword>
  <keyword>BioCryst</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

